|drug1093||Hydroxychloroquine + placebo Wiki||1.00|
|drug2887||meplazumab for injection Wiki||1.00|
|D011024||Pneumonia, Viral NIH||0.13|
|D045169||Severe Acute Respiratory Syndrome NIH||0.05|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Double blinded randomized clinical trial designed to evaluate the efficacy and safety of hydroxychloroquine combined with azithromycin compared to hydroxychloroquine monotherapy in patients hospitalized with confirmed COVID-19 pneumonia.
Description: Evaluation of the clinical status of patient defined by the Ordinal Scale of 7 points (score range from 1 to 7 , with 7 being the worst score)Measure: Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment). Time: up to Day 11
Description: Evaluation of the clinical status of patient defined by the Ordinal Scale of 7 points at day 15 and day 29Measure: Clinical status assessed by ordinal scale Time: up to Day 29
Description: Necessity for transfer to Intensive care unitMeasure: transfer to ICU Time: up to Day 29
Description: days from admission to hospital dischargeMeasure: Length of hospital day Time: up to Day 29
Description: incidence of all-cause mortalityMeasure: Hospital Mortality Time: Day 29
Description: Need to mechanical ventilationMeasure: Need to Mechanical Ventilation Time: up to Day 29
Description: adverse reactionsMeasure: Occurence of grade 3-4 adverse event Time: up to Day 29
Description: ECGMeasure: QTc Lengthening Time: up to Day 11
Description: Thoracic CT scan : number and size of ground-glass opacifications on day 1 and day 11 Two independent pulmonary imagery experts will assess abnormalities according to a standardized frameworkMeasure: Evolution of pulmonary CT scan images Time: up to Day 11